

WITT, OLAF, PROF. DR. MED.

GENERAL INFORMATION



Director Translational Program

Hopp Children's Cancer Center at NCT Heidelberg (KITZ)
Department of Pediatric Oncology, Hematology, Immunology and
Pulmonology, University Hospital Heidelberg
Im Neuenheimer Feld 430, 69120 Heidelberg, Germany

A02

ACADEMIC EDUCATION & QUALIFICATION

Year(s)	Education
1993	3. Staatsexamen Medical School Hamburg
1987-1993	Medical school University of Münster, Hamburg and University of Michigan, Ann Arbor, Michigan, USA

SCIENTIFIC EDUCATION & QUALIFICATION

Year(s)	Education
2002-2006	Board Certification Pediatric Oncology and Hematology
1997-2002	Board Certification for Pediatrics and Neonatal Medicine
1996-2001	Habilitation, University of Göttingen Medical School
1989-1991	MD thesis, University of Münster Medical School

PROFESSIONAL EXPERIENCE

Year(s)	Experience
Since 2016	Director Translational Program, Hopp Children's Cancer Center at NCT Heidelberg
Since 2005	Full Professor (W3) in Pediatric Oncology and Hematology, Division Head – CCU Pediatric Oncology, German Cancer Research Center (DKFZ) Section Head – Phase I/II Clinical Trial Unit and Brain Tumors, Department of Pediatric Oncology, Hematology, Immunology and Pulmonology, University Hospital Heidelberg
2000-2005	University of Göttingen, Department of Pediatrics I: Fellowship and senior attending physician in German Cancer Research Center, Heidelberg
1997-2000	University of Göttingen, Department of Pediatrics I: resident in pediatrics, pediatric oncology and hematology, neonatal care
1995-1997	University of Göttingen, Department of Molecular Biology, Institute of Biochemistry: postdoctoral fellow, Research Stipend of the DFG
1993-1995	Children's Hospital Minden, Germany: resident in pediatrics

OTHER QUALIFICATIONS/ROLES/RESPONSIBILITIES

Year(s)	
2016	Full member, American Society of Clinical Oncology (ASCO)
2015	Associated managing board member GPOH
2013	Full member, International Society of Pediatric Oncology (SIOP)
2012	Chair of the German trial committee for low grade glioma in children
2012	Co-Chair of the European Pre-clinical working group for low-grade glioma in children
2012	Board member of the Phase I/II consortium of the German Society for Pediatric Oncology and Hematology (GPOH)
2010	Full member, German Society for Pediatric Oncology and Hematology (GPOH)
2008	Full member, European Association of Cancer Research (EACR)
2002	Full member, German Society of Pediatrics (DGKM)

SELECTED PUBLICATIONS

1. Gröbner SN, Worst BC, Weischenfeldt J, Buchhalter I, Kleinheinz K,....., Witt H, Burkhardt B, Kratz CP, Witt O, van Tilburg CM, Kramm CM, Fleischhack G, Dirksen U, Rutkowski S, Frühwald M, von Hoff K, Wolf S, Klingebiel T, Koscielniak E, Landgraf P, Koster J, Resnick AC, Zhang J, Liu Y, Zhou X, Waanders AJ, Zwijnenburg DA, Raman P, Brors B, Weber UD, Northcott PA, Pajtler KW, Kool M, Piro RM, Korbel JO, Schlesner M, Eils R, Jones DTW, Lichter P, Chavez L, Zapatka M, Pfister SM; ICGC PedBrain-Seq Project; ICGC MML-Seq Project. The landscape of genomic alterations across childhood cancers. **Nature** 2018;555(7696):321-327
2. Shen J, Najafi S, Stäble S, Fabian J, Koeneke E, Kolbinger FR, Wrobel JK, Meder B, Distel M, Heimbürg T, Sippl W, Jung M, Peterziel H, Kranz D, Boutros M, Westermann F, Witt O, Oehme I. A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment. **Cell Death Differ** 2018 Mar 7. doi: 10.1038/s41418-018-0080-0 [Epub ahead of print]
3. Selt F, Hohloch J, Hielscher T, Sahm F, Capper D, Korshunov A, Usta D, Brabetz S, Ridinger J, Ecker J, Oehme I, Gronych J, Marquardt V, Pauck D, Bächli H, Stiles CD, von Deimling A, Remke M, Schuhmann MU, Pfister SM, Brummer T, Jones DT, Witt O, Milde T. Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing. **Oncotarget** 2017;8(7):11460-11479
4. Worst BC, van Tilburg CM, Balasubramanian GP, Fiesel P, Capper D, Pfister SM, Jones DTW, Witt O. Next-generation personalized medicine for high-risk pediatric cancer patients – the INFORM pilot study. **Eur J Cancer** 2016;65:91-101
5. Bender S et al., International Cancer Genome Consortium PedBrain Tumor Project. Recurrent MET fusion genes represent a drug target in pediatric glioblastoma. **Nat Med** 2016;22(11):1314-1320
6. Selt F, Deiß A, Korshunov A, Capper D, Witt H, van Tilburg CM, Jones DT, Witt R, Sahm F, Reuss D, Kölsche C, Ecker J, Oehme I, Hielscher T, von Deimling A, Kulozik AE, Pfister SM, Witt O, Milde T. Pediatric targeted therapy: Clinical feasibility of personalized diagnostics in children with relapsed and progressive tumors. **Brain Pathol** 2016;26(4):506-16
7. Oehme I, Linke JP, Böck BC, Milde T, Lodrini M, Hartenstein B, Wiegand I, Eckert C, Roth W, Kool M, Kaden S, Gröne HJ, Schulte JH, Lindner S, Hamacher-Brady A, Brady NR, Deubzer HE, Witt O. Histone deacetylase 10 promotes autophagy-mediated cell survival. **Proc Natl Acad Sci U S A** 2013;110(28):E2592-601
8. Schwartzentruber J, Korshunov A, Liu XY, Jones DT, Pfaff E, Jacob K, Sturm D, Fontebasso AM, Quang DA, Tönjes M, Hovestadt V, Albrecht S, Kool M, Nantel A, Konermann C, Lindroth A, Jäger N, Rausch T, Ryzhova M, Korbel JO, Izik AE, Zapatka M, Guha A, Malkin D, Felsberg J, Reifenberger G, von Deimling A, Ichimura K, Collins VP, Witt H, Milde T, Witt O, Zhang C, Castelo-Branco P, Lichter P, Faury D, Tabori U, Plass C, Majewski J, Pfister SM, Jabado N. Identification of recurrent H3 mutations in paediatric high-grade gliomas. **Nature** 2012;482:226-31
9. Milde T, Kleber S, Korshunov A, Witt H, Hielscher T, Koch P, Kopp HG, Jugold M, Deubzer HE, Oehme I, Lodrini M, Gröne HJ, Benner A, Brüstle O, Gilbertson RJ, von Deimling A, Kulozik AE, Pfister SM, Martin-Villalba A, Witt O. A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat. **Acta Neuropathol** 2011;122(5):637-50
10. Milde T, Oehme I, Korshunov A, Kopp-Schneider A, Remke M, Northcott P, Deubzer HE, Lodrini M, Taylor MD, von Deimling A, Pfister S, Witt O. HDAC5 and HDAC9 in medulloblastoma: novel markers for risk stratification and role in tumor cell growth. **Clin Cancer Res** 2010;16(12):3240-52

PATENTS

- Deubzer HE, Ehemann V, Heinrich R, Rönndahl G, Westermann F, Witt O. Means and methods for treating advanced stage neuroblastoma (22.12.2006: PCT/EP2006/069776)
- Deubzer HE and Witt O. Methods for treating and preventing brain tumors based on bone morphogenetic proteins (13.2.2008 US 61/028,731)
- Brady, Witt, Oehme. Histone Deacetylase 10-inhibitor Co-Treatment in Cancer (4.7.2013: PCT/EP2012/075942)

- Rommelaere, Lacroix, Schlehofer, Witt, Deubzer, Kern, Herold-Mende, Geletneky, Leuchs. Use of parvovirus to eliminate cancer stem cells (CSCs; US 2013/0209413A1)